Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: Results of a placebo-controlled double-blind study

Journal of Hepatology

Volumn 28, Issue 5, 1998, Pages 856-864

  Stauch, Sabine ^a   Kircheis, Gerald ^b   Adler, Guideo ^c,d   Beckh, Karlheinz ^c,d   Ditschuneit, Hans ^d   Görtelmeyer, Roman ^b   Hendricks, Rüdiger ^e   Heuser, Albert ^f   Karoff, Christian ^g   Malfertheiner, Peter ^d,h   Mayer, Dirk ^d   Rösch, Wolfgang ^a   Steffens, Jakob ^f  

^a Hospital Nordwest   (Germany)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e General Practice   (Germany)

^f St Elisabeth Hospital   (Germany)

^g Hospital Frankenland   (Germany)

^h University Women's Hospital   (Germany)

Author keywords

Hepatic encephalopathy; Hyperammonemia; L ornithine L aspartate; Number connection test; Placebo controlled clinical trial; Portosystemic encephalopathy index; Subclinical hepatic encephalopathy

Indexed keywords

ORNITHINE ASPARTATE; PLACEBO;

ADULT; AGED; AMMONIA BLOOD LEVEL; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; MALE; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL;

EID: 0032079801     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80237-7     Document Type: Article

References (24)

1. Butterworth RF. Hepatic encephalopathy and brain edema in acute hepatic failure. Does glutamate play a role? Hepatology. 25:1997;1032-1034.
2. Raabe W. Synaptic transmission in ammonia intoxication. Neurochem Pathol. 6:1987;145-166.
3. Butterworth RF. Hepatic encephalopathy. Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter, Shafritz DA. 3rd ed. The Liver: Biology and Pathobiology. 1994;1193-1209 Raven Press, Ltd. New York.
4. Szerb JC, Butterworth RF. Effect of ammonium ions on synaptic transmission in the mammalian central nervous system. Prog Neurobiol. 39:1992;135-153.
5. A response in dissociated rat cortical neurons. Neurosci Lett. 151:1993;51-54.
6. Ha J-H, Basile AS. Modulation of ligand binding to components of the GABAA receptor complex by ammonia: implications for the pathogenesis of hyperammonemic syndromes. Brain Res. 720:1996;35-44.
7. Krieger D, Krieger S, Jansen O, Gass P, Theilmann L, Lichtnecker H. Manganese and chronic hepatic encephalopathy. Lancet. 346:1995;270-274.
8. Vogels BAPM, Maas MAW, Daalhuisen J, Quack G, Chamuleau RAFM. Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats. Hepatology. 25:1997;820-827.
9. Conn HO. The theoretic therapy of hepatic encephalopathy. Conn HO, Bircher J. Hepatic Encephalopathy: Syndromes and Therapies. 1994;135-147 Medi-Ed press, Bloomington, Illinois.
10. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmüller E, Holm E. Effects of ornithine aspartate on plasma ammmonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol. 19:1993;424-430.
11. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 25:1997;1351-1360.
12. Conn HO. Quantifying the severity of hepatic encephalopathy. Conn HO, Bircher J. Hepatic Encephalopathy: Syndromes and Therapies. 1994;13-26 Medi-Ed Press, Bloomington, Illinois.
13. Conn HO. Subclinical hepatic encephalopathy. Conn HO, Bircher J. Hepatic Encephalopathy: Syndromes and Therapies. 1994;27-42 Medi-Ed Press, Bloomington, Illinois.
14. Conn HO. Trailmaking and number connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis. 22:1977;541-550.
15. Da Fonseca-Wollheim F. Direkte Plasmaammoniakbestimmung ohne Enteiweissung. J Clin Chem Clin Biochem. 11:1973;421-431.
16. Hochberg Y, Benjamin Y. More powerful procedures for multiple significance testing. Stat Med. 9:1990;811-818.
17. Kircheis G, Metz M, Frey S, Seiller E. Correlation between pharmacokinetic aspects and clinical efficacy of L-ornithine-L-aspartate (OA): results of randomized controlled clinical trials. J Hepatology. 25:1996;. (Suppl 1): 131 (P/C14/191).
18. Gebhardt R, Beckers G, Gaunitz F, Haupt W, Jonitza D, Klein S, et al. Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels. J Pharmacol Exp Ther. 283:1997;1-6.
19. Stoll B, McNelly Sabine, Buscher HP, Häussinger D. Functional hepatocyte heterogeneity in glutamate, aspartate and α-ketoglutarate uptake: a histoautoradiographical study. Hepatology. 13:1991;247-253.
20. 4-induced liver cell necrosis with no effect on urea synthesis. Chem Biol Interact. 48:1984;191-194.
21. Kaiser S, Gerok W, Häussinger D. Ammonia and glutamine metabolism in human liver slices: new aspects of the pathogenesis of hyperammonemia in chronic liver disease. Eur J Clin Invest. 18:1988;535-542.
22. Girard G, Butterworth RF. Effect of protocaval anastomosis glutamine synthetase activities in liver, brain and skeletal muscle. Dig Dis Sci. 37:1992;1121-1126.
23. Luckhaus C. Auswirkungen von L-ornithin-L-Aspartat auf den Stoffwechsel einiger Aminosäuren und die Fixierung von Ammoniak in der Skelettmuskulatur. Experimentelle Untersuchungen am isoliert perfundierten Rattenhinterkörper. Dissertation. 1995;Medizinische Fakultät der Heinrich-Heine-Universität Düsseldorf.
24. Müting D, Reikowski J. Kontrollierte Studie über die Wirkung einer oral verabreichten ammoniaksenkenden Aminosäure Ornithin-Aspartat auf Leber- und Pankreas-funktion bei Leberzirrhosekranken. Therapiewoche. 30:1980;5990-5996.